Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Impagnatiello MA"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mei M; Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.; Chinese Institutes for Medical Research, Beijing 100069, China., Impagnatiello MA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Jiao J; Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.; Chinese Institutes for Medical Research, Beijing 100069, China., Reiser U; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Tontsch-Grunt U; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Zhang J; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China., Nicklin P; Research Beyond Borders, Boehringer Ingelheim, Biberach an der Riss, Germany., Yu B; Research Beyond Borders, Boehringer Ingelheim, Shanghai 200120, China., Wang Y; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China., He Y; Research Beyond Borders, Boehringer Ingelheim, Shanghai 200120, China., Tan X; Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.; Chinese Institutes for Medical Research, Beijing 100069, China.
Publikováno v:
Protein & cell [Protein Cell] 2024 Jan 03; Vol. 15 (1), pp. 69-75.
Autor:
Kuttruff CA; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Fleck M; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Carotta S; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Bretschneider T; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Dahmann G; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Gremel G; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Grube A; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Handschuh S; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Heimann A; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Impagnatiello MA; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Nar H; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Rast G; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Schaaf O; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria., Schmidt E; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany., Oost T; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Jul 27; Vol. 66 (14), pp. 9376-9400. Date of Electronic Publication: 2023 Jul 14.
Autor:
Pinto C; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Slavic-Obradovic K; Cancer Pharmacology and Disease Positioning, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Fürweger D; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Thaler B; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Souabni A; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Carotta S; Cancer Cell Signaling, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Aichinger M; Cancer Pharmacology and Disease Positioning, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Reiser U; Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Impagnatiello MA; Global BD&L, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Tirapu I; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publikováno v:
IScience [iScience] 2023 Mar 11; Vol. 26 (4), pp. 106381. Date of Electronic Publication: 2023 Mar 11 (Print Publication: 2023).
Autor:
García-Martínez JM; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria. juan_manuel.garcia-martinez@boehringer-ingelheim.com., Wang S; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Weishaeupl C; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Wernitznig A; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Chetta P; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Pinto C; Boehringer Ingelheim Cancer Immunology and Immune Modulation, Vienna, Austria., Ho J; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut., Dutcher D; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut., Gorman PN; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut., Kroe-Barrett R; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut., Rinnenthal J; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Giragossian C; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut., Impagnatiello MA; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Tirapu I; Boehringer Ingelheim Cancer Immunology and Immune Modulation, Vienna, Austria., Hilberg F; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Kraut N; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Pearson M; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria., Kuenkele KP; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Jan; Vol. 20 (1), pp. 96-108. Date of Electronic Publication: 2020 Oct 09.
Autor:
Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com., Mani R; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Engelhardt H; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Impagnatiello MA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Carotta S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kerenyi M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Lorenzo-Herrero S; Department of Functional Biology, Universidad de Oviedo, Instituto de Investigación Biosanitaria del Principado de Asturias (IISPA), IUOPA, Oviedo, Spain., Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Scharn D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Zoephel A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Schnitzer R; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gerstberger T; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Sanderson MP; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Rajgolikar G; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Goswami S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Vasu S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Ettmayer P; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gonzalez S; Department of Functional Biology, Universidad de Oviedo, Instituto de Investigación Biosanitaria del Principado de Asturias (IISPA), IUOPA, Oviedo, Spain., Pearson M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., McConnell DB; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Muthusamy N; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Moll J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Apr; Vol. 19 (4), pp. 1018-1030. Date of Electronic Publication: 2020 Feb 05.
Autor:
Rudolph D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.) dorothea.rudolph@boehringer-ingelheim.com., Impagnatiello MA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Blaukopf C; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Sommer C; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Gerlich DW; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Roth M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Tontsch-Grunt U; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Wernitznig A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Savarese F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Albrecht C; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Geiselmann L; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Reschke M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Garin-Chesa P; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Zuber J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Moll J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Adolf GR; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.)., Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (D.R., M.A.I., U.T.-G., A.W., F.S., M.H.H., C.A., L.G., M.R., P.G.-C., J.M., G.R.A., N.K.); Institute of Molecular Biotechnology, Vienna, Austria (C.B., C.S., D.W.G.); and Research Institute of Molecular Pathology, Vienna, Austria (M.R., J.Z.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2015 Mar; Vol. 352 (3), pp. 579-89. Date of Electronic Publication: 2015 Jan 09.